Merck cancer drug improves survival in phase 3 trial
Merck’s experimental cancer drug sacituzumab tirumotecan significantly improved overall survival in patients with advanced gastroesophageal cancer in a phase 3 trial. The TroFuse-015 trial enrolled 473 patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least two previous lines of systemic therapy. Patients receiving the antibody-drug conjugate, also known as sac-TMT, […] The post Merck cancer drug improves survival in phase 3...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.